SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

SLS009

SLS·SELLAS Life Sciences Group, Inc.
MIXED
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
SLS009 is in Phase 2 testing and has not yet entered a pivotal/registrational trial. If the first-line AML data is positive and the FDA agrees on a registration pathway, a potential NDA filing is likely several years away. The drug could also benefit from Fast Track designation, which enables rolling review and priority review if criteria are met.
Why 6/10
A dated binary catalyst exists: topline data from the Phase 2 first-line AML trial (80 patients) is expected in Q4 2026, within ~2 months. However, SLS009 is not the company's sole value driver; the Phase 3 REGAL trial of galinpepimut-S (GPS) just reached its final analysis trigger and represents a separate major catalyst. The score of 6 reflects a near-term pivotal readout on a significant but not lead asset at a company with multiple programs.
Actionable Insight MIXED

The next hard catalyst for SLS009 is the Phase 2 first-line AML topline data readout expected in Q4 2026 (within approximately 2 months). Positive results could validate SLS009's potential as a backbone AML therapy and significantly boost SLS shares, while negative or mixed data would weigh on the stock. Note that the company's Phase 3 REGAL trial for GPS also just reached its 80th event today, creating a dense catalyst cluster for SLS in the near term.

Price Chart

Loading chart...

Executive Summary

SLS009 (tambiciclib) is a highly selective CDK9 inhibitor being developed by SELLAS Life Sciences Group (NASDAQ: SLS) for acute myeloid leukemia and potentially other cancers. A Phase 2 trial in relapsed/refractory AML met all primary endpoints in July 2025 with a 44-46% overall response rate and median overall survival of 8.9 months, well above historical benchmarks. The company is now running a randomized Phase 2 trial in newly diagnosed first-line AML (80 patients, 28 enrolled as of mid-2026), with topline data expected in Q4 2026 -- the next major catalyst. SLS009 holds FDA Fast Track, Orphan Drug, and two Rare Pediatric Disease Designations. SELLAS has a strong cash position ($138.3M) but no approved products, and both SLS009 and the Phase 3 GPS program (which just triggered final analysis) represent critical value drivers in the near term.

How It Works

SLS009 is a highly selective inhibitor of CDK9, an enzyme that acts as a master switch for gene transcription in cells. Many cancer cells, particularly in acute myeloid leukemia (AML), depend on short-lived proteins like MCL-1 and MYC to survive. By blocking CDK9, SLS009 shuts down production of these proteins, causing cancer cells to die while largely sparing healthy cells. It is designed to overcome resistance to venetoclax, a standard AML drug that becomes less effective when cancer cells increase MCL-1 production.

Trial Status

A Phase 2 trial in relapsed/refractory AML completed and met all primary endpoints (July 2025). A separate randomized Phase 2 trial in newly diagnosed first-line AML (NCT04588922) began enrollment in March 2026, with 28 of 80 patients enrolled as of Q2 2026. Preclinical studies in pancreatic cancer are also underway.

The Two-Sided Case

▲ Bull Case4
Phase 2 r/r AML trial met all primary endpoints with a 44-46% ORR and median overall survival of 8.9 months (vs. ~2.4 months historical benchmark), demonstrating strong proof of concept in a difficult-to-treat population.
FDA granted Fast Track, Orphan Drug, and two Rare Pediatric Disease Designations for SLS009, signaling regulatory interest and potential Priority Review Voucher eligibility upon approval.
The company held $138.3M in cash as of June 30, 2026, providing a multi-year runway to fund both SLS009 and the GPS Phase 3 REGAL program without near-term dilution risk.
Institutional accumulation was heavy in Q2 2026: State Street Corp added 55% to its position, Susquehanna more than doubled, and other large funds (Vanguard, Northern Trust, UBS) added or increased holdings.
▼ Bear Case4
CDK9 inhibitors remain an unproven drug class with no FDA-approved agents; clinical or regulatory setbacks for any CDK9 program could dent confidence in SLS009.
The ongoing first-line AML Phase 2 trial (80 patients) is still enrolling (28 of 80 as of Q2 2026) and the drug has not yet entered a pivotal registration trial, meaning commercial approval is years away at best.
SELLAS has two value-driving programs (GPS Phase 3 and SLS009 Phase 2) and no approved products or revenue; either program's failure would heavily pressure the single-product-company-style valuation.
CDK9 inhibitor competition from AbbVie, Gilead Sciences, and other developers (KB-0742, enitociclib, AZD4573, voruciclib) may crowd the field and set higher efficacy/ safety benchmarks.

Upcoming Catalysts

  • Phase 2 first-line AML topline data readout expected in Q4 2026 (within ~2 months)
  • Q3 2026 earnings report scheduled November 10, 2026
  • Potential clinical development updates for SLS009 in pancreatic cancer following September 2026 preclinical AACR data
  • Any FDA regulatory milestone (e.g., meeting to discuss Phase 2 data and registrational path)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

SELLAS Life Sciences Group, Inc. Press Release SLS ·Originating report

Sources · 11

Hover a chip for the title
1 sellaslifesciences.com2 ir.sellaslifesciences.com3 ir.sellaslifesciences.com4 ir.sellaslifesciences.com5 ir.sellaslifesciences.com6 ir.sellaslifesciences.com7 ir.sellaslifesciences.com8 targetedonc.com9 ir.sellaslifesciences.com10 clinicaltrialvanguard.com11 ashpublications.org